United Therapeutics Corporation(NASDAQ:UTHR) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 28, 2016. Company reported revenue of $412.60M. Analysts estimated a revenue of $394.04M. Earnings per share were $4.55. Analysts had estimated an EPS of $3.18.
In a different note, On Jun 15, 2016, H.C. Wainwright said it Downgrades its rating on United Therapeutics Corporation. In the research note, the firm Lowers the price-target to $175.00 per share. The shares have been rated ‘Neutral’ by the firm. On May 24, 2016, Argus Research said it Downgrades its rating on United Therapeutics Corporation. The shares have been rated ‘Hold’ by the firm.
United Therapeutics Corporation (UTHR) made into the market gainers list on Thursdays trading session with the shares advancing 0.50% or 0.62 points. Due to strong positive momentum, the stock ended at $125.48, which is also near the day’s high of $126.48. The stock began the session at $125.29 and the volume stood at 5,95,140 shares. The 52-week high of the shares is $172.39 and the 52 week low is $97.52. The company has a current market capitalization of $5,454 M and it has 4,34,67,794 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jul 15, 2016, Martine A Rothblatt (Chairman & CEO) sold 1,292 shares at $110.24 per share price.Also, On Jun 10, 2016, Raymond Dwek (director) sold 3,000 shares at $166.28 per share price.On Jun 9, 2016, Tommy G Thompson (director) sold 2,000 shares at $115.62 per share price, according to the Form-4 filing with the securities and exchange commission.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.